Reynolds P M, Sturrock R D, Isaacs A, Hart F D
Rheumatol Rehabil. 1975 May;14(2):67-70. doi: 10.1093/rheumatology/14.2.67.
A short-term double-bind cross-over trial of prenazone 600 mg daily and phenylbutazone 300 mg daily was carried out in twenty out-patients with rheumatoid arthritis. Ten patients preferred prenazone, and eight preferred phenylbutazone. No significant difference in analgesic and antiinflammatory potency was demonstrated under the conditions of the trial, and no serious adverse effects, either clinical or laboratory, were encountered. These findings support other claims that prenazone may be a useful alternative in the treatment of rheumatoid arthritis.
对20名类风湿性关节炎门诊患者进行了一项短期双盲交叉试验，比较每日服用600毫克普瑞松和每日服用300毫克保泰松的效果。10名患者更喜欢普瑞松，8名患者更喜欢保泰松。在试验条件下，未显示出镇痛和抗炎效力有显著差异，也未出现任何严重的临床或实验室不良反应。这些发现支持了其他观点，即普瑞松可能是治疗类风湿性关节炎的一种有用替代药物。
